Major expansions of CD8 hi⍣ CD57 ⍣ T lymphocytes frequently occur during human immunodeficiency virus (HIV) infection and after transplantation. To investigate mechanisms of such cell expansion, we compared the activation and functional status of CD8 hi⍣ CD57 ⍣ and CD57 -peripheral blood lymphocytes (PBL) from normal, bone marrow transplantation (BMT) and HIV ⍣ donors. The CD8 hi⍣ CD57 ⍣ PBL from BMT and HIV ⍣ donors preferentially displayed CD38 and HLA-DR activation markers without correlation between CD8 hi⍣ CD57 ⍣ percentages and HIV load, the CD45RA ⍣ isoform in all ex vivo conditions but acquired CD45RO after in vitro expansion, CD11b and CD11c in BMT and HIV ⍣ donors but decreased expression of CD62-L, VLA-2 and VLA-6. The CD8 hi⍣ CD57 ⍣ cells were positive for perforin and granzyme B and spontaneously mediated cytolytic activity in a CD3-redirected assay. In contrast the inhibitor of cytolytic functions (ICF) produced by CD8 hi⍣ CD57 ⍣ cells down-modulated the CD3-redirected cytolytic activity but only at low levels of CD3 cross-linking. While CD3-triggering induced a low, if any, short-term proliferation of CD8 ⍣ CD57 ⍣ cells, this subset could be amplified after long-term stimulation either with mitogens or with HIV antigens, thereby enriched in HIV-specific T cells producing tumor necrosis factor-α. Altogether these data suggest that CD8 hi⍣ CD57 ⍣ cells represent a terminal differentiation state of activated effector cytotoxic T lymphocytes which are enriched in antigen-specific T cells and down-modulate their own cytolytic potential, thus participating in a negative control of effector cell functions during persistent viral infections or transplantations.
Introduction
In several pathological conditions, a chronic antigen-specific stimulation of CD8 ϩ T cells, due to viral infections [human immunodeficiency virus (HIV) or cytomegalovirus (CMV)] or allogenic transplantations, is associated to major expansions of a particular CD8 cell subset with the CD57 molecule displayed (1) (2) (3) (4) (5) . This subset has been shown to mediate immunoregulatory functions (1, 3, (6) (7) (8) (9) . The antigen-specific priming of cytotoxic T lymphocyte (CTL) precursors induces their differentiation into effector CTL containing cytoplasmic granules of perforin and serine esterase (10) . This effector T cell differentiation includes cell surface expression of the Fas-Fas ligand molecules which participate in an alternative cytolytic pathway (10) . These effector CTL act as serial killers by maintaining their enzymatic potential to mediate the exocytic pathway of cytolysis (10, 11) . They also show increased levels of various adhesion-associated molecules, such as members of the integrin superfamily, the very late antigen (VLA) family or the selectin family. These proteins allow the multistep adhesion process required for tissue infiltration, lymph node recirculation and target cell adhesion (12) (13) (14) . Antigen stimulation induces cell surface expression of various markers such as HLA-DR and CD38 assessing the CTL activation. Moreover, such a stimulation induces the switch from the CD45RA to the CD45RO isoform, believed to be a marker of memory acquisition in CD8 ϩ T cells. However, this opinion is controversial (15) . Acute viral infections resolve rapidly and antigen-specific CD8 ϩ CTL evolve into resting memory T cells with antigen clearance (16) . In contrast, persistent antigen stimulation by chronic viral infections or allogenic transplants maintains chronic activation in cytotoxic effector cells while various mechanisms might limit their cytotoxic cell activity and its immunopathological consequences (17) .
Recurrent signaling through the CD3-TCR complex may result in activation-induced cell death which might be enhanced by the lower expression of the Bcl-2 molecule in memory CD8 ϩ T cells (18) . In addition to that mechanism, CD8 ϩ cell-mediated immune responses can be down-regulated by an altered signal induced by antagonistic peptides (19) or by cell-surface molecules such as killer cell-inhibitory receptors, as recently described (20) . T h 2 cytokines might also participate in the negative regulation of CTL differentiation (21) .
The CD8 ϩ CD57 ϩ cells, initially reported to down-modulate B cell differentiation and CD4 ϩ T cell proliferation, inhibit the CD8 ϩ T cell or NK cell activity (1, 3, (6) (7) (8) (9) . Our group further showed that CD8 ϩ CD57 ϩ T cells mediate this inhibitory activity by releasing a soluble 30 kDa glycoprotein [inhibitor of cytolytic function (ICF)] (1). ICF inhibits the effector phase of the cell-mediated cytolytic process by enhancing cAMP levels in cytolytic effector cells (22) . The CD57 antigen is a highly glycosylated member of the N-CAM family initially described as an NK cell marker. It is also expressed on a few peripheral blood CD3 ϩ CD8 hiϩ CD28 -T cells in normal individuals (Ͻ10%) (23) . A body of evidence suggests that CD57 might also be an activation marker of effector T cells. However, the mechanisms which induce expansion of the CD57 ϩ T cell subset in pathological conditions remain unelucidated. CD8 ϩ CD57 ϩ cell expansion is a constant feature of advanced stages of HIV infection and has been frequently associated with increased expression of the HLA-DR or CD38 activation markers going hand in hand with down-modulation of CD28 on CD8 ϩ T cells (24) (25) (26) (27) . After bone marrow transplantation (BMT), CD8 ϩ CD57 ϩ cell expansion is also frequently correlated with CMV infection (28, 29) . In addition the CD8 ϩ CD57 ϩ lymphocytes can be expanded in vitro after mitogen-activation of peripheral blood mononuclear cells (PBMC) from normal individuals (30) . Of note CD57 can also be expressed in vivo by some activated memory CD4 ϩ T helper cells that are fully differentiated in T h 0/T h 2 cells during HIV infection and transplantation (31) (32) (33) . The CD8 ϩ CD57 ϩ subset displays the cytological characteristics of large granular lymphocytes (LGL). Furthermore, they can mediate killer cell activity after non-specific activation (34) (35) (36) . During CMV infection CMV-specific CTL precursors could be detected both in the CD57 ϩ and CD57 -CD8 ϩ subsets (37) (38) . We demonstrated that CD8 ϩ CD57 ϩ cells infiltrating HIV-infected tissues did not show spontaneous HIV-specific or NK cell cytolytic activity. On the contrary, these cells down-modulated HIV-specific CTL function (9, 22) . Altogether these observations raise the question whether CD8 ϩ CD57 ϩ peripheral blood T cell expansion is driven by antigen-specific activation and subsequent enrichment of antigen-specific CD8 ϩ T cells during chronic immune activation processes (39) .
In order to investigate this question we analyzed the in vivo activation and functional status of CD8 ϩ CD57 ϩ and CD57 -T cells from normal donors, HIV-infected patients and BMT recipients. Moreover, we compared these subsets with in vitro activated PBMC of healthy donors. We show herein that CD8 hiϩ CD57 ϩ cells (i) are activated HLA-DR ϩ and/or CD38 ϩ T lymphocytes that display a different set of adhesion molecules in HIV ϩ and BMT ϩ patients than in normal donors, (ii) are differentiated in vivo into functional cytolytic effector cells containing the cytolytic molecules TiA1, perforin and granzyme B, (iii) can be generated in vitro upon an antigenspecific stimulation and are enriched in antigen-specific T cells secreting tumor necrosis factor (TNF)-α after antigen exposure, and (iv) spontaneously mediate ex vivo a CTL-like cytolytic activity after CD3 triggering which can be downmodulated via an autocrine secretion of the gp30 ICF.
Methods

Patients
A total of 119 allogeneic HLA-matched BMT recipients were studied during the 3 years following BMT from a HLA-identical sibling for hematologic malignancies or severe aplastic anemia. Ninety-six HIV-seropositive patients (as assessed by dual positivity for ELISA and Western blotting) at different stages of HIV disease were studied. Twenty HIV-seronegative blood blank donors were tested as controls.
PBL isolation
Whole blood was washed in PBS (Gibco, Paisley, UK) and lymphocytes were isolated by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) gradient centrifugation. For in vitro generation of CD8 ϩ CD57 ϩ cells, PBL from seronegative donors were stimulated with either 100 U/ml of rIL-2 (Boehringer Mannheim, Mannheim, Germany) or phytohemagglutinin (PHA)-P 1 µg/ ml (Sigma, Saint-Quentin, France) ϩ rIL2 20 U/ml and cultured in RPMI 1640 culture medium (ICN Flow, Irvine, UK) supplemented with 10% FCS (Gibco), 1 mM sodium pyruvate (Gibco), 2 mM L-glutamine (Gibco) and 1% MEM non-essential amino acids (Gibco).
Peptide-specific cell lines
Peptide-specific CTL were derived from HLA-A2 HIV ϩ PBMC co-cultivated with autologous peptide-loaded and irradiated PHA-induced cell lines. Briefly, in order to get stimulatory autologous antigen-presenting cells (APC), PBMC were stimulated with 1 µg/ml PHA-P in RPMI 1640 supplemented as previously described with L-glutamine, sodium pyruvate, antibiotics and 5% pooled human AB serum. After 36-48 h cells were incubated for 2 h with 1 µM of synthetic peptide (HIV-1 Lai-RT 476-484, kindly provided by G. Jung, Tü bingen, Germany) in serum-free medium, irradiated and added in a ratio of 1:5 to defrozen PBMC (1ϫ10 6 /ml). On day 0 of the stimulation, 100 ng/ml of IL7 (R&D Systems, Oxford, UK) was added. At day 4 and every 3 days, rIL2 (20 U/ml) was added. Cells were re-stimulated every 10 days with peptidecoated APC.
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Immunofluorescence analysis
Cell surface antigens were characterized using a standard staining method with the following mAb: CD11a-FITC (25.3), CD11b-FITC (Bear1), CD11c-FITC (BU15), CD18-FITC (7E4), CD25-FITC (33B3.1), CD38-FITC (T16), CD45-RA-FITC (ALB11), CD45RO-Phycoerythrin (PE) (UCHL1), CD54-FITC (84H10), CD57-FITC (NC1), CD57-biotin (NC1), CD58-FITC (AICD58), vascular cell adhesion molecule (VCAM /CD106, 1G11), VLA-2 (Gi9), VLA-4 (HP2.1), VLA-5 (SAM1), VLA-6 (GoH3), Fas (ZB4; Immunotech, Marseille, France), CD62L-PE (TQ1; Coulter, Margency, France), CD4-FITC (Leu3a), CD8-PE (Leu2a), CD8-PerCP (Leu2a), CD2-PE (Leu5b), CD3-PE (Leu4), Goat anti-mouse IgG (GAM)-PE or Red 613-conjugated streptavidin (Becton Dickinson, Pont de Claix, France) were used as second step reagents. Briefly, cells were incubated 20 min. in PBS/0.1% NaN 3 /0.5% BSA, with each mAb as followed: non fluorochrome-conjugated mAb, second step reagents (GAM-PE or Red 613-streptavidin), fluorochrome-conjugated mAb. Each sample was stained with CD8, CD57 and a third mAb. Cells were fixed in PBS/1% paraformaldhehyde (Sigma) before analysis.
For intracytoplasmic staining, cells were incubated in 0.2% PFA for 1 h at 4°C, then centrifuged and reincubated 15 min in PBS/2% FCS/0.2% Tween 20 (Sigma)/10 mM NaN 3 (Sigma) at 37°C. They were resuspended in PBS containing 2% FCS and the primary antibody: either anti-Bcl2 (124; Dako, Versailles, France), anti-TiA1 (Immunotech), anti-perforin (ascitic fluid) or anti-granzyme B (purified antibodies) (kind gifts from L. L. Salsportes, France) and incubated for 30 min at 4°C. Cells were washed twice in PBS containing 2% FCS/ 0.1% Tween 20/10 mM NaN 3 and resuspended in PBS with GAM-PE. After washing twice, cells were incubated in 50 µl PBS containing 10% FCS, CD57-FITC (NC1) (Immunotech) and CD8-PerCP (B9.11) (Immunotech) for 30 min at 4°C. Control cells were incubated with GAM-PE.
Lymphocytes (40,000) were analyzed for three-color fluorescence staining on a cytofluorometer (FACScan; Becton Dickinson) equipped with an argon ion laser exciting fluorochromes at 488 nm, three filters (FL1, BP 530 Ϯ 15 nm; FL2, BP 585 Ϯ 21 nm; and FL3, LP 670 nm) and the CellQuest software.
Peptide-specific stimulation and TNF-α measurement
Cell stimulation. Peptide-specific CTL (1ϫ10 7 ) generated as described above were collected and incubated at 1ϫ10 6 cells/ml with target cells in a 24-well plate. Targets were autologous lymphoblastoid B-Epstein-Barr virus (EBV) cell lines incubated for 2 h with or without the HIV-1 RT peptide 476-484 (10 µM), washed and then added to CTL in an effector:target (E:T) ratio of 2:1. During an overnight contact, Brefeldin A (Sigma) was added (10 mg/ml) to prevent protein secretion.
Cytokine staining. All steps were done at room temperature. Cells (1ϫ10 6 ) were washed in PBS/0.5% BSA and resuspended in 100 µl of PBA/BSA for extracellular staining (20 min) with CD8-PE-Cy5 (B9.11; Immunotech) and CD57-FITC. After washing in PBS/BSA, cells were incubated for 20 min in 500 µl of PFA 4%, washed with PBS/0.5% BSA/0.1% saponin (Sigma) and resuspended in 100 µl of the latter solution for permeabilization. For intracellular staining, anti-TNF-α-PE (6401.1111; Becton Dickinson) was added for 30 min. After an ultimate washing in PBS/BSA, stained cells were resuspended in PBS. Between 50,000 and 100,000 events were analyzed on a flow cytometer (FACScalibur; Becton Dickinson) equipped with an argon ion laser exciting fluorochromes at 488 nm, three filters (FL1, 530 Ϯ 15 nm; FL2, BP 585 Ϯ 21 nm; and FL3, LP 670 nm) and the CellQuest software.
Cell sorting procedures
Immunomagnetic separations of CD8 ϩ CD57 ϩ lymphocytes were performed on fresh PBL from HIV ϩ and BMT patients. Avidin-conjugated magnetic beads (Immunotech) were coupled with biotinylated CD57 mAb as previously described (1, 22) . Cell suspensions were added to these complexes and mixed gently for 45 min at 4°C and CD57 ϩ cells isolated by applying a cobalt magnet (Dynal, Oslo, Norway). The CD57-positive and -negative cell fractions contained Ͼ90% and Ͻ10% CD8 hiϩ CD57 ϩ cells respectively.
FACS was performed on PBMC from BMT recipients resuspended in RPMI 1640 medium at 1ϫ10 7 cells/ml after staining with the anti-CD57-FITC/anti-CD8-PE kit (Immunotech). After two washes, cells were sorted on a FACStar Plus flow cytometer with the Lysys II acquisition system (Becton Dickinson). The CD8 hiϩ CD57 ϩ and CD8 hiϩ CD57 -subsets were restricted to a lymphocyte scatter gate. The purity and viability of each sorted subpopulation was always Ͼ95%.
Production and concentration of ICF
Supernatants (SN) were prepared as described (1, 22) from immunobead-purified CD8 ϩ CD57 ϩ (SN ϩ ) and control CD57 -cells (SN -). Cells were resuspended at 5ϫ10 6 cells/ml in serum-free culture medium (RPMI 1640 supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine), without stimulation and incubated 4 and 18 h at 37°C. Cell suspensions were then centrifuged at 400 g. Resulting SN were ultracentrifugated at 3000 g for 1 h at 4°C using Centricon-10 concentrators (Amicon, Epernon, France) before high speed freezing and storage at -20°C. Concentrations were increased 4 to 10 times.
Proliferation assay
Freshly isolated CD8 ϩ CD57 ϩ and CD8 ϩ CD57 -cells (FACS or immunomagnetic separation) were cultured in RPMI 1640 ϩ 10% FCS at 5ϫ10 4 cells/wells Ϯ anti-CD3 (UCHT1, ascitic fluid kindly given by Professor Beverley, London, UK) Ϯ anti-CD28 (CD28.2, Immunotech) in the presence or absence of rIL2 (Boehringer) at 20 U/ml. At day 3, cultures were pulsed overnight with 1 µCi/well [ 3 H]thymidine (Amersham, Les Ulis, France), harvested on filterglass filtermats (Pharmacia) and radioactivity was measured on a β scintillation counter (Beckman, Gagny, France). Results are represented as c.p.m. triplicates.
Cytolytic assay
Lymphokine-activated killer cells (LAK) were obtained as previously described (1, 22) after a 3 day stimulation. CTL were obtained after PBL isolation from seronegative donors as described above. Target cells (P815, K562 or Daudi) were incubated for 2 h with 70-80 µCi/10 6 cells of Na 2 51 CrO 4 (Amersham). Suspensions of 3000 target cells were added in triplicate to round-bottom 96-well microtiter plates (Costar, Cambridge MA). In the CD3-redirected assays, UCHT1 (ascitic fluid) was added to P815 target cells at dilutions of 1/4000 and 1/8000. Cytolytic effector cells were added at different E:T ratios to determine the E:T ratio giving 20-30% lysis in preliminary standard 51 Cr-release assay. After a 4 h incubation at 37°C, SN were collected and the chromium release was measured on a γ-counter (LKB-Pharmacia, Uppsala, Sweden). The values of spontaneous 51 Cr release were 10-20% of total incorporated radioactivity. Inhibition of cytolytic activity was analyzed after a 1 h preincubation of effector cells with CD8 ϩ CD57 ϩ SN ϩ or control CD57 -SN -(dilution 1/2), prior to the cytolytic assay. The cytolytic assay was performed as described above at a constant E:T ratio ensuring a 20-30% specific lysis. The percentage of 51 Cr-release inhibition was calculated as followed: percentage ϭ 1 -[(experimental -spontaneous release/total radioactivity -spontaneous release)ϫ100].
Plasma HIV load measurement
The detection of HIV RNA load was performed on heparinized samples frozen and stored at -70°C. The assays were realized using the NASBA list (Organon) on 500 µl of plasma to decrease the level of detection at 800 copies/ml. The results were expressed in copies of HIV RNA/ml plasma.
Statistical test
Data analyzed were percentages of positive events within each subset after a lymphocyte gate, recorded on the FACScan (Becton Dickinson) described above and analyzed with Lysys II software. For comparison of the third marker expression on CD8 hiϩ CD57 ϩ lymphocytes versus their CD8 hiϩ CD57 -counterpart, whatever their origin (normal, HIV ϩ or BMT donors), and on CD8 hiϩ CD57 ϩ cells from HIV ϩ and BMT donors versus CD8 hiϩ CD57 ϩ cells from normal controls was analyzed. As data number was Ͻ5, the non-parametric Mann-Whitney U-test was performed.
Results
In vivo and in vitro expansion of CD8 hiϩ CD57 ϩ T lymphocytes
We analyzed 96 HIV ϩ donors and 119 BMT recipients with CD8 hiϩ CD57 ϩ T lymphocyte expansion from two cohorts of HIV ϩ individuals and of BMT HIV -recipients. A similar expansion of CD8 hiϩ CD57 ϩ cells was observed within PBL from HIV ϩ patients and BMT recipients with mean values of 24 Ϯ 9 and 25 Ϯ 12% respectively, that significantly differed from those observed in 10 normal controls (mean:7 Ϯ 5%). A CD4 lymphopenia was observed in both groups, but no significant correlation was found between the increase in CD8 hiϩ CD57 ϩ and the CD4 ϩ cell depletion either in HIV ϩ donors or in BMT recipients (Fig. 1A) . Similarly we observed no significant correlation between CD8 hiϩ CD57 ϩ cell expansion in HIV ϩ patients and the HIV plasma viral load as analyzed by quantitative RT-PCR measurement (data not shown).
We could reproduce a slight CD8 hiϩ CD57 ϩ cell expansion in vitro by stimulating PBMC from normal donors with PHA ϩ IL-2 or IL-2 alone. The CD8 hiϩ CD57 ϩ cell expansion occurred at 2-4 weeks after a transient disappearance from day 2 to 13, although reaching lower percentages than observed ex vivo in HIV ϩ or BMT patients, and represented a 10-to 30-fold absolute expansion of the CD8 hiϩ CD57 ϩ cells (Fig. 1B) . A similar in vitro expansion could be reproduced for PBMC from HIV ϩ or BMT recipients with similar kinetics up to the initial CD8 hiϩ CD57 ϩ levels observed in PBL from those donors (data not shown).
We then tested the effects of an antigen-specific stimulation using HIV peptides on CD8 hiϩ CD57 ϩ cells from HIV-infected patients. HIV ϩ PBMC, with 22% of CD8 hiϩ CD57 ϩ lymphocytes at day 0 (Fig.1C, left panel) , were stimulated in vitro with autologous APC coated with an HIV-1 LAI-RT HLA-A2-restricted peptide (476-484), known for its high immunogenicity (40) . The kinetics of CD8 hiϩ CD57 ϩ cell expansion in vitro was similar to the mitogenic amplification. Indeed, between day 7 and 20, after two sets of peptide-specific stimulation, CD8 ϩ CD57 ϩ lymphocytes represented only 12% of the culture, but rose up to 28% after the third antigenspecific stimulation at day 30 (Fig. 1C, right panel) , representing an 11-fold expansion in absolute numbers of CD8 ϩ CD57 ϩ lymphocytes. As a comparison, CD8 hiϩ CD57 -lymphocytes, that represented 37% of total PBMC at day 0, reached 42% after the third stimulation. Altogether, these data suggest that the expansion of CD8 hiϩ CD57 ϩ cells might result from long-term activation and proliferation of CD8 hiϩ CD57 -cells.
In vivo and in vitro activation status of CD8 hiϩ CD57 ϩ T cells
We then investigated whether the CD8 hiϩ CD57 ϩ cells observed ex vivo during HIV infection or after BMT displayed characteristics of activated T cells. We compared by threecolor immunofluorescence analysis T cell activation markers on the CD8 hiϩ CD57 ϩ and CD8 hiϩ CD57 -T lymphocytes in fresh PBMC from normal, HIV ϩ and BMT patients with the CD8 hiϩ CD57 ϩ cells amplified in vitro from normal PBMC. The low HLA-DR expression observed on resting CD8 hiϩ CD57 ϩ PBMC from normal individuals contrasted with a strong increase in HLA-DR positivity after in vitro activation while proportions of CD8 hiϩ CD57 ϩ HLA-DR ϩ cells were increased in HIV-infected or BMT patients. HLA-DR expression was not restricted to the CD57 ϩ subset since a similar pattern of HLA-DR expression was observed on both CD57 ϩ and CD57 -subsets (Fig. 2) . In all cases CD38 expression on CD8 ϩ CD57 ϩ cells was predominating over HLA-DR expression, but was significantly increased only on HIV ϩ donors' cells as compared to controls. Looking at CD45 isoform usage, we observed a significantly higher positivity for CD45RA and a lower positivity for CD45RO on the CD8 hiϩ CD57 ϩ cells from HIV ϩ donors and BMT recipients than on their CD57 -counterpart. In contrast, in vitro expanded CD8 hiϩ CD57 ϩ cells predominantly displayed the CD45RO isoform (Fig. 2) . A fourcolor immunofluorescence analysis on HIV ϩ donor's cells allowed us to observe co-expression of the two CD45RA and CD45RO isoforms representing 18-26% on CD8 hiϩ CD57 ϩ cells and 9-12% on CD8 hiϩ CD57 -(data not shown).
The Bcl-2 and Fas molecules that are involved in protection or induction of activation-induced cell death have been shown to be respectively down-and up-modulated in CD45RO ϩ CD8 hiϩ T cells (18) . We compared Bcl-2 and Fas expression on CD8 hiϩ CD57 ϩ and CD8 hiϩ CD57 -cells in the different conditions tested. No significant difference was observed in the intra-cytoplasmic Bcl-2 (70-90%) or the cell surface Fas (50-70%) expression between both subsets nor between normal and HIV ϩ or BMT CD8 hiϩ CD57 ϩ cells (data not shown), suggesting that CD8 ϩ CD57 ϩ cell expansion in vivo does not result from a distinct sensitivity of CD8 hiϩ CD57 ϩ cells rather than their CD57 -counterpart to apoptosis.
Expression of adhesion molecules on CD8 hi CD57 ϩ T lymphocytes
We then analyzed three groups of adhesion molecules: (i) the integrin β 2 group (CD18 and its dimers: CD11a, CD11b and CD11c), (ii) the integrin β 1 group (VLA antigens: CD49b/ VLA2, CD49d/VLA4, CD49e/VLA5 and CD49f/VLA6) and (iii) four members of the Ig superfamily (CD54/ICAM-1, CD58/ LFA3, CD106/VCAM and CD62L/L-Selectin).
We observed in all conditions that both CD8 hiϩ CD57 ϩ and CD8 hiϩ CD57 -cells normally co-express the CD18 and CD11a molecules, with no differences in the fluorescence intensity between the two subsets (data not shown), while a preferential expression of CD11b (MAC-1/CR3) was significant on the CD8 hiϩ CD57 ϩ subset as compared to CD57 -cells. As similar results were observed on normal, HIV ϩ and BMT patients' peripheral blood cells (Fig. 3) , we concluded that CD11b overexpression is subset specific. An increased proportion of the CD8 hiϩ CD57 ϩ T cells positive for CD11c (p150-95) was significant on HIV ϩ donors' cells only, compared to their CD57 -counterpart or with normal or BMT CD8 hiϩ CD57 ϩ cells (data not shown). The VLA-2 was down-modulated on CD8 hiϩ CD57 ϩ cells compared to CD57 -cells while the VLA-4 and VLA-5 expression was similar on both subsets, whatever the donor origin (data not shown). In addition, when compared to normal individual cells, the VLA-2 and VLA-6 expression was further decreased on CD8 hiϩ CD57 ϩ cells from HIV ϩ infected donors, suggesting a disease-specific alteration.
With regard to the Ig superfamily group, normal CD8 hiϩ CD57 ϩ cells differed from their CD57 -counterpart by an up-regulated CD58/LFA-3 expression. This ratio was reversed in HIV ϩ and BMT patients' cells where almost all CD8 hiϩ CD57 -cells were positive for LFA-3 (P Ͻ 0.05). In contrast the in vitro activated CD8 ϩ T cells showed no LFA-3 expression whether they were CD57 ϩ or CD57 -. Conversely CD8 hiϩ CD57 ϩ cells were positive for CD54/ICAM-1 only after in vitro activation (data not shown). Finally, CD62L/L-selectin was preferentially expressed on normal resting CD8 hiϩ CD57 ϩ cells compared to CD57 -cells, although in low proportions. This difference disappeared in HIV ϩ donors' and BMT recipients' cells, where CD62-L expression decreased on the CD8 hiϩ CD57 ϩ subset but was enhanced on CD8 hiϩ CD57 -cells (Fig. 3) . Fig. 2 . Activation status of normal donors, HIV-infected patients, BMT recipients, and in vitro generated CD8 hiϩ CD57 ϩ and CD8 hiϩ CD57 -T cells. Fresh PBMC from three normal donors, three HIV-infected patients and three BMT recipients (mean of CD8 ϩ CD57 ϩ cells: 3 Ϯ 1, 25 Ϯ 5 and 21 Ϯ 4% respectively) were analyzed for activation marker positivity in a CD8 hiϩ CD57 ϩ and in a CD8 hiϩ CD57 -gate. PBMC from normal individuals were activated in vitro as described in Methods, and tested between day 20 and 30 post-stimulation. Mean percentage of positive cells in CD8 hiϩ CD57 ϩ T cells (black bars) and CD8 hiϩ CD57 -T cells (cross-hatched bars) is represented with SD (white bars). Significant differences (P Ͻ 0.05) according to Mann-Whitney U-test between CD8 hiϩ CD57 ϩ and CD8 hiϩ CD57 -cells from the same origin are indicated by asterisks, while significant differences (P Ͻ 0.05) between CD8 hiϩ CD57 ϩ or CD8 hiϩ CD57 -cells from BMT recipients, HIV ϩ donors or activated normal culture and their normal counterpart are marked 'p'.
CD3 triggering does not induce proliferation of in vivo expanded CD8 hiϩ CD57 ϩ cells
We then investigated whether the CD8 ϩ CD57 ϩ cells from BMT and HIV ϩ donors that were already expanded in vivo could proliferate in vitro after cross-linking of their CD3-TCR complex. The CD8 hiϩ CD57 ϩ subset was sorted from BMT recipient PBMC either by immunomagnetic beads or by FACS (Fig. 4) . CD3 triggering induced a poor proliferation of both CD57 ϩ and CD57 -CD8 hiϩ cells, whatever the purification procedure. Interestingly the addition of exogenous IL-2 failed to potentiate CD8 hiϩ CD57 ϩ cell proliferation while inducing a 3-fold increase of the CD57 -subset. Similarly, co-triggering of the CD28 molecule did not enhance CD8 hiϩ CD57 ϩ cell proliferation, an observation in accordance with the low CD28 positivity of this subset (2-15%, data not shown). Such a low CD3-induced proliferative capacity of the CD8 hiϩ CD57 ϩ T lymphocytes expanded in vivo was in line with the transient disappearance we observed between day 2 and 13 during in vitro generation of CD8 hiϩ CD57 ϩ lymphocytes we described (Fig. 1B) .
CD8 hiϩ CD57 ϩ T lymphocytes are differentiated in vivo into mature functional cytotoxic effector T lymphocytes
We then investigated whether CD8 hiϩ CD57 ϩ cells might have reached a terminal stage of T cell differentiation in vivo. For that purpose we first looked for the presence of intracytoplasmic molecules involved in cytolysis (such as perforine and granzyme B) by three-color immunofluorescence. As shown in Table 1 , CD8 hiϩ CD57 ϩ T lymphocytes from HIV ϩ and BMT donors displayed a 80-90% positivity for both molecules without prior in vitro activation. Such reactivity was not modified after a 3 day culture with IL-2, except for a slight increase in the perforine positivity. This suggested that the CD8 hiϩ CD57 ϩ T lymphocytes from HIV ϩ donors and BMT recipients were already differentiated in vivo into effector cytotoxic T cells.
To investigate the functionality of such cytotoxic cells, sorted CD8 hiϩ CD57 ϩ T lymphocytes from BMT recipients were tested in a CD3-redirected assay against the murine FcR-bearing myeloma P815 target cells. Both CD8 hiϩ CD57 ϩ and CD57 -T lymphocytes, either from fresh PBMC or after a PHA-P activa- Fig. 3 . Expression of adhesion molecules on CD8 hiϩ CD57 ϩ and CD8 hiϩ CD57 -T lymphocytes from normal donors, HIV-infected patients and BMT recipients. Fresh PBMC from three normal donors, three HIV ϩ patients and three BMT recipients (mean of CD8 hiϩ CD57 ϩ cells: 3 Ϯ 1, 25 Ϯ 5 and 21 Ϯ 4% respectively) were analyzed for activation marker positivity in a CD8 hiϩ CD57 ϩ and a CD8 hiϩ CD57 -gate. PBMC from normal individuals were activated in vitro as described in Methods, and tested between day 20 and 30 post-stimulation. The same legends as Fig. 2 . tion, displayed a potent redirected cytotoxicity against anti-CD3-coated P815 cells (Fig. 5) . In contrast LAK cell-mediated cytotoxicity against the Daudi target cells could only be evidenced after a 3 day culture with IL-2 (data not shown). Such analysis could not be performed on fresh CD8 hiϩ CD57 ϩ T lymphocytes from normal donors because of the low number of available cells. However, very low if any redirected cytolytic activity could be spontaneously detected either in whole PBMC or in purified CD8 ϩ cells from normal donors (data not shown).
CD8 hiϩ CD57 ϩ T lymphocytes can down-regulate their cytotoxic potential
The capacity of the CD3 triggering to induce cytotoxic activity in CD8 hiϩ CD57 ϩ T lymphocytes contrasted with the previously reported capacity of CD8 hiϩ CD57 ϩ T lymphocytes to block NK cell and CTL activity by releasing a soluble glycoproteic ICF (1, 9, 22) . A similar inhibitory activity could be generated after in vitro expansion of CD8 hiϩ CD57 ϩ lymphocytes (data not shown). Therefore, we investigated whether the CD3 triggering of cytolysis was also sensitive to the effect of ICF produced by CD8 hiϩ CD57 ϩ cell from HIV ϩ infected patients and BMT recipients. We first confirmed that the CD8 hiϩ CD57 ϩ T lymphocyte culture SN inhibited LAK cell-mediated lysis of Daudi target cells while CD8 hiϩ CD57 -SN was unable to do so. We then investigated whether the intensity of the CD3 triggering might overcome the ICF inhibitory activity. We demonstrated that the CD8 hiϩ CD57 ϩ T lymphocyte SN inhibited CD3-redirected lysis in a dose-dependant manner (Fig. 6 ) only when the latter was triggered at low concentrations of anti-CD3 (1/8000) but not at the higher concentration of 1/ 4000 that has been previously used to trigger cytolysis in the sorted CD8 hiϩ CD57 ϩ T cell subset (Fig. 5) . As control, no inhibition was observed when a culture SN from CD8 hiϩ CD57 -T lymphocytes was tested, whatever the anti-CD3 concentration used. Altogether, these data clearly show that CD8 hiϩ CD57 ϩ T lymphocytes amplified in vivo are differentiated into mature functional cytotoxic T cells that produce in parallel ICF, a soluble glycoprotein capable of counteracting their cytolytic activity.
CD8 hiϩ CD57 ϩ cells expanded in vitro are enriched in antigenspecific T cells
Altogether our results described above suggest that the CD8 hiϩ CD57 ϩ T cells could be expanded both in vitro and in vivo after antigen stimulation, and acquire the phenotypic and functional characteristics of effector CTL. We then investigated whether they represented antigen-specific CD8 ϩ T cells in the CD8 ϩ cell line specific for the HIV-1 RT HLA-A2-restricted epitope (476-484) we described above (Fig. 1C) . Because of restrictions in sorting facilities for HIV-infected cells, we were not able to evaluate their capacity to mediate peptide-specific lysis in a standard 51 Cr assay. We thus tested their capacity to produce TNF-α in presence of autologous APC coated with the HIV-1 RT 476-484 peptide. We observed a progressive enrichment in the proportions of CD8 ϩ T cells able to produce TNF-α: after three stimulations, 12% of the total CD8 ϩ T cells reacted against this peptide (Fig. 7) and after the fourth one this percentage rose up to 34%. As Fig. 5 . CD8 hiϩ CD57 ϩ T lymphocytes mediate 'CTL-like' cytotoxic activities. CD8 hiϩ CD57 ϩ (squares) and CD8 hiϩ CD57 -(triangles) sorted lymphocytes from BMT recipients were tested for cytotoxic activity in an anti-CD3-redirected cytotoxicity assay against 51 Cr-labeled P815 target cells, in the presence (close symbols) or absence (open symbols) of anti-CD3 mAb at various E:T ratios. Cells were sorted either on freshly harvested PBMC (A) or after in vitro pre-activation (B). Fig. 6 . The CD8 hiϩ CD57 ϩ cell SN inhibits anti-CD3-redirected and LAK lysis. Effector killer cells were generated in vitro from normal PBMC by culture with rhIL-2 100 U/ml; LAK cells were tested at day 3 against Daudi, or with PHA-P ϩ rhIL-2 20 U/ml, and CTL-like cells were tested against anti-CD3 coated-P815 target cells. Two dilutions [1/4000 (close symbols) and 1/8000 (open symbols)] of antiCD3 mAb were tested. The CD8 hiϩ CD57 ϩ (squares) and CD8 hiϩ CD57 -(triangles) cell SN were added to effector cells 1 h before the 51 Crrelease assay.
control, no or few (Ͻ5%) CTL incubated with APC alone produced TNF-α. Moreover, we showed that 42% of CD8 ϩ CD57 ϩ T in the total CD8 ϩ CD57 ϩ subset were recruited for producing TNF-α upon antigen stimulation while only 30% of the CD8 ϩ CD57 -T cells were induced to produce TNF-α in the CD8 ϩ CD57 -subset (Fig. 7) . Taken together, these data demonstrate that CD8 ϩ CD57 ϩ T cells, when expanded in vitro after an antigen-specific stimulation, are enriched in antigenspecific T cells.
Discussion
In this study we investigated whether the frequent and massive expansion of peripheral blood CD8 hiϩ CD57 ϩ T cells occurring in vivo during persistent antigenic stimulation by viruses or transplants might result from chronic CD8 ϩ cell activation and the differentiation of these cells into antigen-specific cytotoxic effector T cells. We showed that accumulation of CD8 hiϩ CD57 ϩ T cells is indeed associated to a particular profile of activation cell markers. This profile was assessed by enhanced positivity for HLA-DR or CD38 molecule, either ex vivo after BMT and during HIV infection or after in vitro activation. Such cell activation markers are thought to reflect viral replication and antigenic stimulation, as suggested by their disparition with anti-retroviral therapy (42) . Nevertheless we could not find herein any significant correlation between CD8 ϩ CD57 ϩ cell expansion and viral load. The higher CD8 ϩ cell positivity for CD38 than for HLA-DR that we observed on CD8 ϩ CD57 ϩ T cells from HIV-infected patients was in accordance with the continuous rise of CD8 ϩ CD38 ϩ T cells known to occur with HIV disease progression (24, 41, 42) . However, we could not significantly correlate CD8 hiϩ CD57 ϩ T cell expansion with CD4 cell depletion despite the low CD4 counts of the patients tested in our study (range 4-110/mm 3 ) (24) . On the contrary, we previously reported that CD8 ϩ CD57 ϩ cell expansion was correlated with the disappearance of HIVspecific effector CTL activity during progression toward AIDS (9) . Similarly, the CD8 ϩ CD57 ϩ cell increase observed after BMT is a constant feature of CMV infection as previously reported by our group and others (28, 29) . However, this increase could not be correlated with either CD4 lymphopenia, active CMV disease or graft versus host disease.
The CD8 hiϩ CD57 ϩ T cells expanded in vivo had not switched their CD45 isoforms as a consequence of prior antigen priming, but rather preferentially displayed the CD45RA isoform and/or co-expressed both RA and RO molecules. Such preferential CD45RA expression observed after disease-related expansion contrasted with the predominant expression of the CD45RO isoform after in vitro stimulation of CD8 ϩ CD57 ϩ cells. However, the hypothesis that CD8 hiϩ CD57 ϩ T cell expansion is composed of memory T cells cannot be rejected since the validity of the CD45RA/RO as markers of naive/memory CD8 ϩ cells is not as well defined for CD8 ϩ T cells as for CD4 ϩ T cells (11, 43) . Furthermore, L- Fig. 7 . CD8 hiϩ CD57 ϩ cells expanded upon an RT-specific stimulation are enriched in antigen-specific T cells. CD8 ϩ T cells were producing TNF-α after an overnight incubation with autologous EBV coated with HIV-1 RT peptide (B) while no TNF-α secretion was induced when the same CD8 ϩ T cells were incubated with autologous EBV alone (A). When analyzing these CD8 ϩ TNF-α ϩ cells gated in R2 (lower panel), we showed that 42% of total CD8 ϩ CD57 ϩ T cells were induced to produce TNF-α after antigen-specific stimulation. Of note, CD8 ϩ CD57 ϩ T cells represented 29% of total cells and a probability of 20% was used for scale.
selectin was also down-regulated on CD8 hiϩ CD57 ϩ cells but up-regulated in the CD57 -subset from HIV ϩ donors and BMT recipients. L-selectin is known to be up-regulated on naive CD4 ϩ T cells and on a subset of memory CD4 ϩ T cells in terminal differentiation in mice (45) allowing cellular adhesion to the Gly-CAM/Mad-CAM receptors on high endothelial venules (44) . Although these latter characteristics have yet to be applied to the human CD8 ϩ T cell subset, the low L-selectin expression on CD8 ϩ T cells reported during HIV infection has been interpreted as a consequence of massive switch toward memory cells (46) . We also observed a decrease in β1 integrin expression, such as VLA-2 and VLA-6, on CD8 hiϩ CD57 ϩ T cells from HIV ϩ donors (14, 47) . This might alter, together with L-selectin modifications, the circulation routes of the CD8 hiϩ CD57 ϩ subset within lymph nodes or tissues (48) . In contrast the β 2 integrin CD11b and CD11c molecule expression was enhanced on HIV-infected patients and in BMT recipients. This up-regulation remains on enhanced CD11c expression on activated T cell clones (49) or on LGL (34) . Nevertheless, the increased LFA-3 expression we report was in line with previous reports on HIV infection (24) .
According to the weak expression of CD45RO, both CD8 hiϩ CD57 ϩ and CD57 -subsets showed the same level of Bcl-2 expression, a molecule known to be down-regulated in CD8 ϩ CD45RO ϩ T cells during viral infections (18) . Additionally, the lack of increase in Fas expression suggested no increased commitment to apoptosis as well. These latter observations indicate that the CD8 hiϩ CD57 ϩ T cell expansion that occurs in vivo is not a passive cellular accumulation resulting from a lower sensitivity to antigen-induced cell death than their CD57 -counterpart. On the contrary, our data suggest that the CD8 hiϩ CD57 ϩ subset amplified in vivo displays some characteristics of activated lymphocytes even if they lack some phenotypic markers of memory T cells. However, up to now it is still controversial as to which markers are necessary for human CD8 ϩ memory T cells.
CD3 triggering induced a weak proliferation of CD8 hiϩ CD57 ϩ cells in accordance with the transient disappearance of these lymphocytes noted between day 2 and 6 of the in vitro cultures. Nevertheless, it contrasted with the CD8 hiϩ CD57 ϩ cell amplification observed after three or four antigenic stimulations. These observations suggest that CD57 can appear on CD8 ϩ cell surface as the result of long-term activation. Furthermore, neither the addition of IL-2 nor CD28 co-stimulation could rescue the short-term proliferation of CD8 hiϩ CD57 ϩ cells which lacked both CD28 and CD25 expression (52) . CD28 down-modulation on CD8 hiϩ CD57 ϩ cells might reflect recurrent T cell activation (52, 53) . This has been shown to be a feature of senescent CD8 ϩ cells during HIV infection (54, 55) . Finally, CD8 hiϩ CD57 ϩ cell amplification can be reproduced in vitro. However, this in vitro culture shows a transient decrease following the initial stimulus and reaches lower percentages than observed in vivo during HIV infection or after BMT. Altogether these observations suggest that the CD57 molecule might appear on CD8 ϩ T cells as the result of long-term activation and proliferation of CD57 -T cells that have reached a terminal differentiation stage while losing their capacity to proliferate. Furthermore, our report shows that CD8 hiϩ CD57 ϩ T cells from HIV ϩ and BMT donors are fully differentiated into cytolytic effector T cells in vivo as expected from their characteristics of LGL. Indeed these cells spontaneously displayed perforin and granzyme B, confirming that this subset has developed in vivo the enzymatic machinery involved in the exocytic pathway of cytolysis. Using a CD3-redirected assay which mimics antigen-specific cytolysis we demonstrated that CD8 hiϩ CD57 ϩ cells can deliver a CTL-like cytolytic function upon massive triggering of their CD3 complex while no NK cell activity was observed without in vitro pre-activation (9) . Additionally, specific antigen stimulation of these CD8 hiϩ CD57 ϩ cells could trigger TNF-α production which is known to be associated with cytolytic processes (59) . Such CTL differentiation and activity of CD8 hiϩ CD57 ϩ T cells is in contrast with the previously reported ability of these cells to inhibit CTL, NK and LAK cell cytolytic functions (1, 22, 29) . We showed herein that the massive cross-linking of the CD3 molecules used in the CD3 redirected assay might be able to overcome the inhibitory activity of the ICF molecule spontaneously produced by the same cells. ICF indeed blocked the CD3-redirected cytolysis but only when low concentrations of anti-CD3 antibody were used for triggering. This inhibitory property of CD8 hiϩ CD57 ϩ cells observed at low intensity of CD3 triggering might be physiologically relevant since T cells need as few as 100 MHC-peptide complexes expressed to recognize target cells (56) . Our observations clearly demonstrate that CD8 hiϩ CD57 ϩ cells have a dual functional differentiation combining, on one hand, the cytolytic potential and, on the other hand, a striking capacity to block cytolytic functions.
We previously showed that this subset lacked effector CTL activity directed against the HIV-1 envelope glycoprotein (9) . Similarly HIV-specific CTL were recently shown to be CD57 - (57) . In contrast, studies of CMV-specific CTL responses showed an equal frequency of CMV-specific CTL precursors in the CD8 ϩ CD57 ϩ and CD8 ϩ CD57 -subsets from normal healthy individuals (37) . Oligoclonality of the peripheral CD8 ϩ CD57 ϩ subset has recently been confirmed in CMVinfected patients (37) . This finding is in accordance with our previous observation of a remarkable restriction of TCR V β usage by CD8 ϩ CD57 ϩ cells after BMT where a striking homology in the CDR3 regions of the TCR among several donors had suggested a common antigen specificity among those cells (51, 58) . In line with such hypothesis, the new observations we report here clearly show that the CD8 hiϩ CD57 ϩ subset can be enriched in antigen-specific cells after recurrent antigen stimulation.
Taken together, our results suggest that these CD8 hiϩ CD57 ϩ T cells represent a terminal differentiation step of antigen-specific CTL that continuously arise during persistent viral infections or after transplantation. These cells have lost their clonogenic potential and are involved in a negative control of cell-mediated cytotoxicity, thus participating in the mechanisms used by the immune system to limit tissue damage induced by chronically activated cytotoxic effector T cells. 
